NASDAQ Stock Exchange News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 706,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "35fcbbeb-90ec-4d30-bda9-66ff1d653d74",
"title": "Q4 2023 Vivos Therapeutics Inc Earnings Call Transcript",
"description": "Mar 28, 2024 / 09:00PM GMTOperator Good day, everyone, and welcome to Vivos Therapeutics Fourth Quarter and Full Year 2020 Conference Call. (Operator Instructio",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NAS:VVOS",
"snippet": "Mar 28, 2024 / 09:00PM GMT\n\nOperator\n\n\n\nGood day, everyone, and welcome to Vivos Therapeutics Fourth Quarter and Full Year 2020 Conference Call. (Operator Instr...",
"url": "https://www.gurufocus.com/news/2401215/q4-2023-vivos-therapeutics-inc-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-03-29T14:03:15.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "VVOS",
"name": "Vivos Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 143.79424,
"sentiment_score": 0.460033,
"highlights": [
{
"highlight": "Mar 28, 2024 / 09:00PM GMT\n\nOperator\n\n\n\nGood day, everyone, and welcome to <em>Vivos</em> <em>Therapeutics</em> Fourth Quarter and Full Year 2020 Conference Call.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Julie Gannon - <em>Vivos</em> <em>Therapeutics</em> <em>Inc</em> - Investment Relations Officer\n\n\n\nThank you, operator. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.gevo.com.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Q4 2023 <em>Vivos</em> <em>Therapeutics</em> <em>Inc</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "b6285b4a-346d-4aa8-8e9d-a260a99c7483",
"title": "Lululemon Is Fairly Valued After Double-Digit Drop",
"description": "Shares of Lululemon Athletica Inc. (LULU) experienced a nearly 16% drop in a single day after the company released full-year guidance that fell below analysts'",
"keywords": "GuruFocus, Article, News, Hung Tran, LULU",
"snippet": "Shares of Lululemon Athletica Inc. (LULU, Financial) experienced a nearly 16% drop in a single day after the company released full-year guidance that fell below...",
"url": "https://www.gurufocus.com/news/2396234/lululemon-is-fairly-valued-after-doubledigit-drop",
"image_url": "https://static.gurufocus.com/photos/others/Lululemon 12.8.14.jpg",
"language": "en",
"published_at": "2024-03-29T14:00:01.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LULU",
"name": "Lululemon Athletica Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 39.66743,
"sentiment_score": 0.76515,
"highlights": [
{
"highlight": "Shares of <em>Lululemon</em> <em>Athletica</em> <em>Inc</em>. (LULU, Financial) experienced a nearly 16% drop in a single day after the company released full-year guidance that fell below analysts' expectations on March 21.\n\nHowever, looking over a broader timeline, the retailer has been a great compounder.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Conclusion\n\nOver the past decade, <em>Lululemon</em> <em>Athletica</em> has demonstrated outstanding achievements in growing revenue, enhancing profitability, generating strong cash flows, maintaining a solid balance sheet and delivering a high return on invested capital.",
"sentiment": 0.8934,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "3714f9c0-12b8-42ba-a254-e7d4b54c2df0",
"title": "Wall Street On Edge With Momentum Trade Wrapping Up Historic Quarter",
"description": "The simplest stock strategy on Wall Street — beloved by the smartest minds in finance and more — just closed out its best quarter in more than two decades.",
"keywords": "NVDA:US, WBD:US, GPS:US, JPM:US, 8266222Z:US, DJT:US, ALLTOP, CORONAVIR, ECOTOP, MKTTOP, STKTOP, TOP, WWTOP, WWTOPAM, WWTOPAS, WWTOPEU",
"snippet": "These kinds of projections have misfired again and again with high performers like Meta Platforms Inc. posting an earnings bonanza. Yet any sharp rotation out o...",
"url": "https://www.ndtvprofit.com/business/wall-street-on-edge-as-momentum-trade-wraps-up-historic-quarter",
"image_url": "https://media.assettype.com/bloombergquint%2F2024-03%2Fcd8652e5-1107-4020-8823-05662f03793f%2Flo_lo_CeVj8lPBJSc_unsplash.jpg?w=320&h=180&auto=format%2Ccompress&ogImage=true",
"language": "en",
"published_at": "2024-03-29T13:21:44.000000Z",
"source": "bloombergquint.com",
"relevance_score": null,
"entities": [
{
"symbol": "META",
"name": "Meta Platforms Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 19.641895,
"sentiment_score": 0.5325,
"highlights": [
{
"highlight": "These kinds of projections have misfired again and again with high performers like <em>Meta</em> <em>Platforms</em> <em>Inc</em>. posting an earnings bonanza. Yet any sharp rotation out of the winners in favor of the losers — a potentially healthy outcome for the broader market — would come at a particularly painful time.",
"sentiment": 0.5325,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "d1222647-758b-4eea-8d12-e843c5044e91",
"title": "Celsius May Be Too Frothy Here - Wait For A Deep Pullback (NASDAQ:CELH)",
"description": "Celsius could be the next big thing in the global energy drink market, attributed to its impressive share gains against incumbents, such as MNST and Red Bull. Read more here.",
"keywords": "",
"snippet": "Jonathan Knowles/DigitalVision via Getty Images\n\nThe CELH Long-Term Investment Thesis Is Highly Promising, Though Overly Inflated Here\n\nCelsius Holdings (NASDAQ...",
"url": "https://seekingalpha.com/article/4681177-celsius-holdings-stock-impressive-gains-but-valuation-expensive",
"image_url": "https://media.gettyimages.com/id/1275822751/photo/close-up-frothy-beer-bubbles.jpg?b=1&s=170667a&w=0&k=20&c=13hyE02EMrHtKTFzkWIY-NFaV5kd2Yd9czhzZXyNntQ=",
"language": "en",
"published_at": "2024-03-29T13:15:00.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "MNST",
"name": "Monster Beverage Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 21.13859,
"sentiment_score": 0.8993,
"highlights": [
{
"highlight": "Jonathan Knowles/DigitalVision via Getty Images\n\nThe CELH Long-Term Investment Thesis Is Highly Promising, Though Overly Inflated Here\n\nCelsius Holdings (NASDAQ:CELH) could be the next big thing in the global energy drink market, attributed to its impressive share gains against incumbents such as <em>Monster</em> <em>Beverage</em> <em>Corporation</em> (MNST) and privately owned",
"sentiment": 0.8993,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "510ae343-96c0-42fd-9782-a5515c5f6d42",
"title": "Pacific Premier Bancorp, Inc. to Announce First Quarter 2024 Financial Results on April 24, 2024 By Investing.com",
"description": "Pacific Premier Bancorp, Inc. to Announce First Quarter 2024 Financial Results on April 24, 2024",
"keywords": "",
"snippet": "IRVINE, Calif.--(BUSINESS WIRE)--Pacific Premier Bancorp, Inc. (Nasdaq: PPBI) (\" Pacific Premier \"), the holding company of Pacific Premier Bank, announced toda...",
"url": "https://www.investing.com/news/press-releases/pacific-premier-bancorp-inc-to-announce-first-quarter-2024-financial-results-on-april-24-2024-93CH-3358036",
"image_url": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
"language": "en",
"published_at": "2024-03-29T13:12:09.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "PPBI",
"name": "Pacific Premier Bancorp, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 157.9034,
"sentiment_score": 0.154457,
"highlights": [
{
"highlight": "--(BUSINESS WIRE)--<em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>. (<em>Nasdaq</em>: <em>PPBI</em>) (\" Pacific Premier \"), the holding company of Pacific Premier Bank, announced today that it will issue its first quarter 2024 financial results before the market opens on Wednesday, April 24, 2024.\n\nPacific Premier will also host a conference call at 9:00 a.m. PT / 12:00 p.m.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "ET\n\nTelephone Access:\n\nUnited States: 1-866-290-5977\n\nInternational: 1-412-902-4111\n\nCanada: 1-855-669-9657\n\nParticipants should ask to be joined into the <em>Pacific</em> <em>Premier</em> <em>Bancorp</em> (NASDAQ: ), Inc. call.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "webcastid=zXdm6KLR\n\nAbout <em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>.\n\n<em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>PPBI</em>) is the parent company of Pacific Premier Bank, a California-based commercial bank focused on serving small, middle-market, and corporate businesses throughout the western United States in major metropolitan markets in California, Washington, Arizona, and Nevada.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "For additional information about <em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>. and Pacific Premier Bank, visit our website: www.ppbi.com.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240329021287/en/\n\n<em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>.\n\nSteven R. Gardner\n\nChairman, Chief Executive Officer, and President\n\n949-864-8000\n\nRonald J.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Lazzaro\n\nSenior Vice President, Director of Investor Relations\n\n949-243-1082\n\nSource: <em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>. to Announce First Quarter 2024 Financial Results on April 24, 2024 By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "f244f125-1428-4ade-8402-2fcd94fe2da3",
"title": "Popular, Inc. to Report First Quarter Results and Hold Conference Call on Tuesday, April 23, 2024 By Investing.com",
"description": "Popular, Inc. to Report First Quarter Results and Hold Conference Call on Tuesday, April 23, 2024",
"keywords": "",
"snippet": "SAN JUAN, Puerto Rico--(BUSINESS WIRE)--Popular, Inc. (NASDAQ: BPOP) announced today that it expects to report its financial results for the first quarter endin...",
"url": "https://www.investing.com/news/press-releases/popular-inc-to-report-first-quarter-results-and-hold-conference-call-on-tuesday-april-23-2024-93CH-3358032",
"image_url": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
"language": "en",
"published_at": "2024-03-29T13:12:08.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "BPOP",
"name": "Popular, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 54.376213,
"sentiment_score": 0.22798,
"highlights": [
{
"highlight": "SAN JUAN, Puerto Rico--(BUSINESS WIRE)--<em>Popular</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>BPOP</em>) announced today that it expects to report its financial results for the first quarter ending March 31, 2024, before the market opens on Tuesday, April 23, 2024.\n\nPopular will hold a conference call to discuss the financial results the same day at 11:00 a.m. Eastern Time.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Popular</em>, <em>Inc</em>.\n\n<em>Popular</em>, <em>Inc</em>. is the leading financial institution by both assets and deposits in Puerto Rico and ranks among the top 50 U.S. bank holding companies by assets. Founded in 1893, Banco Popular de Puerto Rico, Popular's principal subsidiary, provides retail, mortgage and commercial banking services in Puerto Rico and the U.S.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "View source version on businesswire.com: https://www.businesswire.com/news/home/20240329451909/en/\n\n<em>Popular</em>, <em>Inc</em>.\n\nInvestor Relations:\n\nPaul J.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Cardillo, 212-417-6721\n\nSenior Vice President and Investor Relations Officer\n\nor\n\nMedia Relations:\n\nMC González Noguera, 917-804-5253\n\nExecutive Vice President and Chief Communications & Public Affairs Officer\n\nSource: <em>Popular</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em>, <em>Inc</em>. to Report First Quarter Results and Hold Conference Call on Tuesday, April 23, 2024 By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "BPOPO",
"name": "Popular, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 51.655495,
"sentiment_score": 0.152567,
"highlights": [
{
"highlight": "SAN JUAN, Puerto Rico--(BUSINESS WIRE)--<em>Popular</em>, <em>Inc</em>. (NASDAQ: BPOP) announced today that it expects to report its financial results for the first quarter ending March 31, 2024, before the market opens on Tuesday, April 23, 2024.\n\n<em>Popular</em> will hold a conference call to discuss the financial results the same day at 11:00 a.m. Eastern Time.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Popular</em>, <em>Inc</em>.\n\n<em>Popular</em>, <em>Inc</em>. is the leading financial institution by both assets and deposits in Puerto Rico and ranks among the top 50 U.S. bank holding companies by assets. Founded in 1893, Banco <em>Popular</em> de Puerto Rico, Popular's principal subsidiary, provides retail, mortgage and commercial banking services in Puerto Rico and the U.S.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em> also offers in Puerto Rico auto and equipment leasing and financing, investment banking, broker-dealer and insurance services through specialized subsidiaries.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "In the mainland United States, <em>Popular</em> provides retail, mortgage and commercial banking services through its New York-chartered banking subsidiary, <em>Popular</em> Bank, which has branches located in New York, New Jersey and Florida.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240329451909/en/\n\n<em>Popular</em>, <em>Inc</em>.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Cardillo, 212-417-6721\n\nSenior Vice President and Investor Relations Officer\n\nor\n\nMedia Relations:\n\nMC González Noguera, 917-804-5253\n\nExecutive Vice President and Chief Communications & Public Affairs Officer\n\nSource: <em>Popular</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em>, <em>Inc</em>. to Report First Quarter Results and Hold Conference Call on Tuesday, April 23, 2024 By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "9423e378-a61d-4e1e-93cc-884cbecc22b8",
"title": "Pacific Premier Bancorp, Inc. to Announce First Quarter 2024 Financial Results on April 24, 2024",
"description": "Pacific Premier Bancorp, Inc. , the holding company of Pacific Premier Bank, announced today that it will issue its first quarter 2024 financial results before the market opens on Wednesday, April...",
"keywords": "Markets",
"snippet": "Pacific Premier Bancorp, Inc. (Nasdaq: PPBI) (\"Pacific Premier\"), the holding company of Pacific Premier Bank, announced today that it will issue its first quar...",
"url": "https://www.marketscreener.com/quote/stock/PACIFIC-PREMIER-BANCORP-I-10522/news/Pacific-Premier-Bancorp-Inc-to-Announce-First-Quarter-2024-Financial-Results-on-April-24-2024-46319942/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-03-29T13:01:05.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "FRGAP",
"name": "Franchise Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 12.257358,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "Pacific Premier Bank also offers a wide array of loan products, such as commercial business loans, lines of credit, SBA loans, commercial real estate loans, agribusiness loans, <em>franchise</em> lending, home equity lines of credit, and construction loans.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PPBI",
"name": "Pacific Premier Bancorp, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 166.01994,
"sentiment_score": 0.1802,
"highlights": [
{
"highlight": "<em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>. (<em>Nasdaq</em>: <em>PPBI</em>) (\"Pacific Premier\"), the holding company of Pacific Premier Bank, announced today that it will issue its first quarter 2024 financial results before the market opens on Wednesday, April 24, 2024.\n\nPacific Premier will also host a conference call at 9:00 a.m. PT / 12:00 p.m.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "ET\n\nTelephone Access:\n\nUnited States: 1-866-290-5977\n\nInternational: 1-412-902-4111\n\nCanada: 1-855-669-9657\n\nParticipants should ask to be joined into the <em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>. call.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "webcastid=zXdm6KLR\n\nAbout <em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>.\n\n<em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>PPBI</em>) is the parent company of Pacific Premier Bank, a California-based commercial bank focused on serving small, middle-market, and corporate businesses throughout the western United States in major metropolitan markets in California, Washington, Arizona, and Nevada.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "For additional information about <em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>. and Pacific Premier Bank, visit our website: www.ppbi.com.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240329021287/en/",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pacific</em> <em>Premier</em> <em>Bancorp</em>, <em>Inc</em>. to Announce First Quarter 2024 Financial Results on April 24, 2024",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "ef7204d9-58d6-435a-8228-eb98e6cb0ec8",
"title": "Popular, Inc. to Report First Quarter Results and Hold Conference Call on Tuesday, April 23, 2024",
"description": "Popular, Inc. announced today that it expects to report its financial results for the first quarter ending March 31, 2024, before the market opens on Tuesday, April 23, 2024.\n\n\nPopular will hold a...",
"keywords": "Markets",
"snippet": "Popular, Inc. (NASDAQ: BPOP) announced today that it expects to report its financial results for the first quarter ending March 31, 2024, before the market open...",
"url": "https://www.marketscreener.com/quote/stock/POPULAR-INC-10686498/news/Popular-Inc-to-Report-First-Quarter-Results-and-Hold-Conference-Call-on-Tuesday-April-23-2024-46319943/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-03-29T13:01:05.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "BPOP",
"name": "Popular, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 57.730766,
"sentiment_score": 0.379967,
"highlights": [
{
"highlight": "<em>Popular</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>BPOP</em>) announced today that it expects to report its financial results for the first quarter ending March 31, 2024, before the market opens on Tuesday, April 23, 2024.\n\nPopular will hold a conference call to discuss the financial results the same day at 11:00 a.m. Eastern Time.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Popular</em>, <em>Inc</em>.\n\n<em>Popular</em>, <em>Inc</em>. is the leading financial institution by both assets and deposits in Puerto Rico and ranks among the top 50 U.S. bank holding companies by assets. Founded in 1893, Banco Popular de Puerto Rico, Popular’s principal subsidiary, provides retail, mortgage and commercial banking services in Puerto Rico and the U.S.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em>, <em>Inc</em>. to Report First Quarter Results and Hold Conference Call on Tuesday, April 23, 2024",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "BPOPO",
"name": "Popular, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 54.657574,
"sentiment_score": 0.18308,
"highlights": [
{
"highlight": "<em>Popular</em>, <em>Inc</em>. (NASDAQ: BPOP) announced today that it expects to report its financial results for the first quarter ending March 31, 2024, before the market opens on Tuesday, April 23, 2024.\n\n<em>Popular</em> will hold a conference call to discuss the financial results the same day at 11:00 a.m. Eastern Time.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Popular</em>, <em>Inc</em>.\n\n<em>Popular</em>, <em>Inc</em>. is the leading financial institution by both assets and deposits in Puerto Rico and ranks among the top 50 U.S. bank holding companies by assets. Founded in 1893, Banco <em>Popular</em> de Puerto Rico, Popular’s principal subsidiary, provides retail, mortgage and commercial banking services in Puerto Rico and the U.S.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em> also offers in Puerto Rico auto and equipment leasing and financing, investment banking, broker-dealer and insurance services through specialized subsidiaries.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "In the mainland United States, <em>Popular</em> provides retail, mortgage and commercial banking services through its New York-chartered banking subsidiary, <em>Popular</em> Bank, which has branches located in New York, New Jersey and Florida.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240329451909/en/",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em>, <em>Inc</em>. to Report First Quarter Results and Hold Conference Call on Tuesday, April 23, 2024",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "71ed6a88-721b-4d65-8fd8-7c4c20092b8a",
"title": "BurgerFi to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024 By Investing.com",
"description": "BurgerFi to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024",
"keywords": "",
"snippet": "FORT LAUDERDALE, Fla., March 29, 2024 (GLOBE NEWSWIRE) -- BurgerFi International, Inc. (NASDAQ: BFI, BFIIW) (BurgerFi), owner of one of the nation's leading fas...",
"url": "https://www.investing.com/news/press-releases/burgerfi-to-report-fourth-quarter-and-fiscal-year-2023-financial-results-on-april-1-2024-93CH-3358005",
"image_url": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
"language": "en",
"published_at": "2024-03-29T12:12:08.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "FRGAP",
"name": "Franchise Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 11.492212,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "Anthony's is a premium pizza and wing brand with 60 restaurants (59 corporate-owned casual restaurant locations and 1 dual brand <em>franchise</em> location), as of January 1, 2024.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BFI",
"name": "BurgerFi International, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 74.77399,
"sentiment_score": 0.04562,
"highlights": [
{
"highlight": "., March 29, 2024 (GLOBE NEWSWIRE) -- <em>BurgerFi</em> <em>International</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>BFI</em>, BFIIW) (BurgerFi), owner of one of the nation's leading fast-casual better burger dining concepts through the BurgerFi brand, and the high-quality, casual dining pizza brand under the name Anthony's Coal Fired Pizza & Wings (Anthony's), will report financial results for the fourth quarter and fiscal year ended January 1, 2024 on Monday",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>BurgerFi</em> <em>International</em> (<em>Nasdaq</em>: <em>BFI</em>, BFIIW)<em>BurgerFi</em> <em>International</em>, <em>Inc</em>. is a leading multi-brand restaurant company that develops, markets, and acquires fast-casual and premium-casual dining restaurant concepts around the world, including corporate-owned stores and franchises.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BurgerFi</em> <em>International</em> is the owner and franchisor of the two following brands with a combined 168 locations.\n\nAnthony's. Anthony's is a premium pizza and wing brand with 60 restaurants (59 corporate-owned casual restaurant locations and 1 dual brand franchise location), as of January 1, 2024.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Investor Relations:ICRMichelle [email protected]\n\nMedia Relations Contact:Ink Link MarketingKim Miller [email protected]\n\nSource: <em>BurgerFi</em> <em>International</em>",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "e8566092-388e-45aa-9cf7-a90bc8048c0f",
"title": "Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update By Investing.com",
"description": "Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update",
"keywords": "",
"snippet": "- Data for masked anti-CTLA-4 SAFEbody ® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsat...",
"url": "https://www.investing.com/news/press-releases/adagene-reports-full-year-2023-financial-results-and-provides-corporate-update-93CH-3358040",
"image_url": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
"language": "en",
"published_at": "2024-03-29T13:12:07.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "EXEL",
"name": "Exelixis, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.484165,
"sentiment_score": 0.636533,
"highlights": [
{
"highlight": "with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 -\n\n\n\n- Ongoing combination phase 2 dose expansion in MSS CRC increased to over 50 patients, including initiation of a new, unprecedented 20 mg/kg loading dose regimen, with data anticipated during 2024 -\n\n- Validation of SAFEbody masking technology by <em>Exelixis</em>",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "COLLABORATIONS\n\n<em>Exelixis</em>: In June 2023, Adagene received a US$3.0 million milestone payment from <em>Exelixis</em> for the successful nomination of lead SAFEbody candidates for the second collaboration program under a technology licensing agreement to develop novel masked antibody-drug conjugate candidates.",
"sentiment": 0.8519,
"highlighted_in": "main_text"
},
{
"highlight": "The increase of approximately 95% reflects net revenue recognized upon fulfillment of certain performance obligations associated with the collaboration and technology licensing agreements with <em>Exelixis</em> and Sanofi, respectively. Net revenue also included a milestone payment of US$3.0 million from <em>Exelixis</em> received in June 2023.",
"sentiment": 0.7845,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "b9daeb76-7b8a-4107-9643-10c328d23d31",
"title": "Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates By Investing.com",
"description": "Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates",
"keywords": "",
"snippet": "ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024\n\nELI-007 and ELI-008 preclinical data were accep...",
"url": "https://www.investing.com/news/press-releases/elicio-therapeutics-reports-2023-financial-results-and-provides-corporate-updates-93CH-3358021",
"image_url": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
"language": "en",
"published_at": "2024-03-29T12:40:08.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "ANGN",
"name": "Angion Biomedica Corp.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 25.225185,
"sentiment_score": 0.8126,
"highlights": [
{
"highlight": "The reduction in net loss per share was primarily due to an increase in weighted average common shares outstanding as a result of the reverse merger with <em>Angion</em> <em>Biomedica</em> <em>Corp</em>. in June 2023.\n\nCash and cash equivalents as of December 31, 2023, were $12.9 million, compared to $6.2 million as of December 31, 2022.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "49021a38-3e90-4604-8d86-bb69b18f65ba",
"title": "Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update By Investing.com",
"description": "Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update",
"keywords": "",
"snippet": "AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates (NASDAQ: ), Inc. (Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmac...",
"url": "https://www.investing.com/news/press-releases/molecular-templates-inc-reports-fourth-quarter-2023-financial-results-and-business-update-93CH-3358018",
"image_url": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
"language": "en",
"published_at": "2024-03-29T12:32:08.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "MTEM",
"name": "Molecular Templates, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 141.50284,
"sentiment_score": 0.1428,
"highlights": [
{
"highlight": "AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- <em>Molecular</em> <em>Templates</em> (NASDAQ: ), Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>MTEM</em>, <em>Molecular</em> <em>Templates</em>, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Templates</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Templates</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Molecular</em> <em>Templates</em>\n\n<em>Molecular</em> <em>Templates</em> is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Templates</em> disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "In addition, when or if used in this press release, the words may, could, should, continue, anticipate, potential, believe, estimate, appears, expect, intend, plan, predict and similar expressions and their variants, as they relate to <em>Molecular</em> <em>Templates</em> may identify forward-looking statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to the following: the continued availability of financing on commercially reasonable terms, whether <em>Molecular</em> <em>Templates</em>' cash resources will be sufficient to fund its continuing operations; the",
"sentiment": 0.1016,
"highlighted_in": "main_text"
},
{
"highlight": "results of MTEM's ongoing clinical studies and the ability to effectively operate MTEM, and those risks identified under the heading Risk Factors in <em>Molecular</em> <em>Templates</em>' filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the year ended December 31, 2023 and any subsequent reports filed with the SEC.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Any forward-looking statements contained in this press release speak only as of the date hereof, and <em>Molecular</em> <em>Templates</em> specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.\n\nContacts:[email protected]\n\nSource: <em>Molecular</em> <em>Templates</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Molecular</em> <em>Templates</em>, <em>Inc</em>. Reports Fourth Quarter 2023 Financial Results and Business Update By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "BMY",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 21.818874,
"sentiment_score": 0.47965,
"highlights": [
{
"highlight": "Key Milestones for 2024\n\nClinical data on MT-6402 expansion cohorts in low and high PD-L1+ HNSCC patients\n\nClinical data from dose escalation study for MT-8421 Treg depleting agent in solid tumors\n\n<em>Bristol</em>-<em>Myers</em> <em>Squibb</em> (NYSE: ) Collaboration Agreement\n\nOn March 13, 2024, <em>Bristol</em>-<em>Myers</em> <em>Squibb</em> notified the Company that following a corporate portfolio",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with <em>Bristol</em>-<em>Myers</em> <em>Squibb</em> and grant revenue.\n\nTotal research and development expenses for the fourth quarter of 2023 were $8.8 million, compared with $17.6 million for the same period in 2022.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "cd73bb3e-b7d9-4691-bd3f-3218754ceda1",
"title": "Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update By Investing.com",
"description": "Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update",
"keywords": "",
"snippet": "NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: NASDAQ: ), the leading developer of therapeutics that target galectin pro...",
"url": "https://www.investing.com/news/press-releases/galectin-therapeutics-reports-2023-financial-results-and-provides-business-update-93CH-3358010",
"image_url": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
"language": "en",
"published_at": "2024-03-29T12:12:07.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "GALT",
"name": "Galectin Therapeutics Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 88.36633,
"sentiment_score": 0.062475,
"highlights": [
{
"highlight": "., March 29, 2024 (GLOBE NEWSWIRE) -- <em>Galectin</em> <em>Therapeutics</em>, <em>Inc</em>. (NASDAQ: NASDAQ: ), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Joel Lewis, Chief Executive Officer and President of <em>Galectin</em> <em>Therapeutics</em>, said We have been focused on advancing our Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) cirrhosis program.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Galectin</em> <em>Therapeutics</em>\n\n<em>Galectin</em> <em>Therapeutics</em> is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Company Contact:\n\nJack Callicutt, Chief Financial Officer(678) [email protected]\n\nInvestors Relations Contacts:Kevin [email protected]\n\nChris [email protected]\n\n<em>Galectin</em> <em>Therapeutics</em> and its associated logo is a registered trademark of <em>Galectin</em> <em>Therapeutics</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Belapectin is the USAN assigned name for <em>Galectin</em> <em>Therapeutics</em>' galectin-3 inhibitor belapectin.",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Consolidated Balance Sheet Data\n\nDecember 31, 2023 December 31, 2022 (in thousands) Cash and cash equivalents $ 25,660 $ 18,592 Total assets 28,200 21,285 Total current liabilities 15,676 13,012 Total liabilities 88,441 53,479 Total redeemable, convertible preferred stock 1,723 1,723 Total stockholders' equity (deficit) $ (61,964 ) $ (33,917 )\n\nSource: <em>Galectin</em>",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Therapeutics</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Galectin</em> <em>Therapeutics</em> Reports 2023 Financial Results and Provides Business Update By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "0fb73f7c-7462-4c56-bee6-6a1167b4b8d9",
"title": "SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results By Investing.com",
"description": "SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results",
"keywords": "",
"snippet": "Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results\n\nMarch 29, 2024\n\nSAB-142 Phase 1...",
"url": "https://www.investing.com/news/press-releases/sab-biotherapeutics-reports-full-year-2023-operating-and-financial-results-93CH-3357998",
"image_url": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
"language": "en",
"published_at": "2024-03-29T11:28:07.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "EDIT",
"name": "Editas Medicine, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 14.029329,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Lucera, a 30-year veteran of the biotechnology and medical device industry, has held executive positions at several healthcare companies, most recently as Chief Financial Officer of <em>Editas</em> <em>Medicine</em> (NASDAQ: ).\n\n(NASDAQ: ).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "c9c8268c-7312-4b32-b89f-b4e685779a75",
"title": "Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023 By Investing.com",
"description": "Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023",
"keywords": "",
"snippet": "Viactiv ® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared...",
"url": "https://www.investing.com/news/press-releases/guardion-health-sciences-announces-financial-results-for-the-year-ended-december-31-2023-93CH-3357984",
"image_url": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
"language": "en",
"published_at": "2024-03-29T10:28:07.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "BEST",
"name": "BEST Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 6.961092,
"sentiment_score": 0.305325,
"highlights": [
{
"highlight": "Recent Developments in 2024\n\nAgreement to Sell Activ Nutritional, LLC\n\nOn January 30, 2024, the Company entered into an Equity Purchase Agreement (the Purchase Agreement) with Doctor's <em>Best</em> <em>Inc</em>., a Delaware corporation, for the sale of all of the outstanding equity interests of Activ Nutritional, LLC (Activ) for aggregate cash consideration of $17.2",
"sentiment": 0.9081,
"highlighted_in": "main_text"
},
{
"highlight": "Doctor's <em>Best</em> <em>Inc</em>. is a wholly-owned subsidiary of Kingdomway USA Corp., the U.S. subsidiary holding company of Xiamen Kingdomway Group Company (XKDW), which is publicly listed on the Shenzhen Stock Exchange.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the successful completion of the sale of Activ to Doctor's <em>Best</em>",
"sentiment": 0.339,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>., the use of the proceeds received from the sale, the Company's ability to continue to fund its operations, including its ocular healthcare business, subsequent to the sale, any replacement and integration of new management team members, the implementation of new financial, management, accounting and business software systems, supply chain disruptions",
"sentiment": -0.0258,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GHSI",
"name": "Guardion Health Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 121.78165,
"sentiment_score": 0.2665,
"highlights": [
{
"highlight": "Viactiv ® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022\n\nHOUSTON, TEXAS, March 29, 2024 (GLOBE NEWSWIRE) -- <em>Guardion</em> <em>Health</em> <em>Sciences</em>, <em>Inc</em>.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>GHSI</em>) (Guardion or the Company), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the year ended December 31, 2023.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Guardion</em> <em>Health</em> <em>Sciences</em>, <em>Inc</em>.\n\n<em>Guardion</em> <em>Health</em> <em>Sciences</em>, <em>Inc</em>. (<em>Nasdaq</em>: <em>GHSI</em>) is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients.",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about <em>Guardion</em> <em>Health</em> <em>Sciences</em>, <em>Inc</em>.,¯Contact:\n\[email protected]\n\n\n\nPhone: 1-800 873-5141 Ext 208",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardion</em> <em>Health</em> <em>Sciences</em> Announces Financial Results for the Year Ended December 31, 2023 By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "002626.SZ",
"name": "Xiamen Kingdomway Group Company",
"exchange": null,
"exchange_long": null,
"country": "cz",
"type": "equity",
"industry": "Healthcare",
"match_score": 23.715092,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., the U.S. subsidiary holding company of <em>Xiamen</em> <em>Kingdomway</em> <em>Group</em> <em>Company</em> (XKDW), which is publicly listed on the Shenzhen Stock Exchange.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "44e4039b-148d-40ad-a960-be1b6759f71b",
"title": "Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments",
"description": "Estimated Earnings Per Share: Analysts projected a loss of $0.16 per share, while actual loss was $0.74 per share.Estimated Net Income: The estimated net loss",
"keywords": "GuruFocus, Article, News, GuruFocus Research, GALT",
"snippet": "On March 29, 2024, Galectin Therapeutics Inc (GALT, Financial), a leader in the development of therapeutics targeting galectin proteins, released its 8-K filing...",
"url": "https://www.gurufocus.com/news/2401174/galectin-therapeutics-inc-galt-reports-2023-financial-results-and-business-developments",
"image_url": "https://static.gurufocus.com/logos/0C000008LZ.png?5",
"language": "en",
"published_at": "2024-03-29T13:11:28.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GALT",
"name": "Galectin Therapeutics Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 144.58676,
"sentiment_score": 0.117467,
"highlights": [
{
"highlight": "On March 29, 2024, <em>Galectin</em> <em>Therapeutics</em> <em>Inc</em> (GALT, Financial), a leader in the development of therapeutics targeting galectin proteins, released its 8-K filing, disclosing its financial results for the year ended December 31, 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Galectin</em> <em>Therapeutics</em> <em>Inc</em> is a clinical-stage biopharmaceutical company focused on the development of new therapies for fibrotic disease, cancer, and other diseases. Its lead galectin-3 inhibitor, belapectin (GR-MD-02), has shown promise in preclinical models to reverse liver fibrosis and cirrhosis.",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Despite not generating revenue, <em>Galectin</em> <em>Therapeutics</em> has managed to reduce its general and administrative expenses and has benefitted from a $10 million credit facility provided by Chairman Richard Uihlein.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "With a focus on developing novel therapies for chronic liver disease and cancer, <em>Galectin</em> <em>Therapeutics</em> aims to leverage its scientific and development expertise to efficiently advance its clinical programs.",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "For detailed financial tables and further information on <em>Galectin</em> <em>Therapeutics</em> Inc's financial performance, readers are encouraged to view the full 8-K filing.\n\nExplore the complete 8-K earnings release (here) from <em>Galectin</em> <em>Therapeutics</em> <em>Inc</em> for further details.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Galectin</em> <em>Therapeutics</em> <em>Inc</em> (GALT) Reports 2023 Financial Results and Business Developments",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "90f057ba-0037-4a95-b42c-b438c55d1013",
"title": "Q4 2023 Iterum Therapeutics PLC Earnings Call Transcript",
"description": "Mar 28, 2024 / 12:30PM GMTOperator Hello, everyone, and welcome to the Iterum Therapeutics fourth quarter and full year 2023 financial results and business upda",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NAS:ITRM",
"snippet": "Mar 28, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nHello, everyone, and welcome to the Iterum Therapeutics fourth quarter and full year 2023 financial results and business...",
"url": "https://www.gurufocus.com/news/2400190/q4-2023-iterum-therapeutics-plc-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-03-29T05:04:17.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ITRM",
"name": "Iterum Therapeutics plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 165.57605,
"sentiment_score": 0.459433,
"highlights": [
{
"highlight": "Mar 28, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nHello, everyone, and welcome to the <em>Iterum</em> <em>Therapeutics</em> fourth quarter and full year 2023 financial results and business update. My name is Emily, and I'll be coordinating your call. (Operator Instructions)\n\n\n\nI will now turn the call over to our host, Louise Barrett, Senior Vice President of Legal Affairs.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Louise Barrett - <em>Iterum</em> <em>Therapeutics</em> <em>plc</em> - SVP, Legal Affairs\n\n\n\nThank you, Emily. Good morning and welcome to <em>Iterum</em> <em>Therapeutics</em>' fourth quarter and full year 2023 financial results and business update conference call. Our press release for our fourth quarter and full results was issued earlier this morning and can be found on our website.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "Q4 2023 <em>Iterum</em> <em>Therapeutics</em> <em>PLC</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "04b73c1c-446d-4f0b-b9b8-8de1a9738979",
"title": "Q4 2023 Agile Therapeutics Inc Earnings Call Transcript",
"description": "Mar 28, 2024 / 12:30PM GMTOperator Good morning, and welcome to the Agile Therapeutics Fourth Quarter and Full Year 2023 financial results conference call. Plea",
"keywords": "GuruFocus, Article, News, GuruFocus Research, OTCPK:AGRX",
"snippet": "Mar 28, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nGood morning, and welcome to the Agile Therapeutics Fourth Quarter and Full Year 2023 financial results conference call....",
"url": "https://www.gurufocus.com/news/2400187/q4-2023-agile-therapeutics-inc-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-03-29T05:04:13.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AGRX",
"name": "Agile Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 143.15182,
"sentiment_score": 0.452967,
"highlights": [
{
"highlight": "Mar 28, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nGood morning, and welcome to the <em>Agile</em> <em>Therapeutics</em> Fourth Quarter and Full Year 2023 financial results conference call. Please note, today's event is being recorded I would now like to turn the conference over to Matt Reilly, Head of Investor Relations. Please go ahead.",
"sentiment": 0.9001,
"highlighted_in": "main_text"
},
{
"highlight": "Matthew Riley - <em>Agile</em> <em>Therapeutics</em> <em>Inc</em> - Head of Investor Relations, Corporate Communications\n\n\n\nHello, everyone, and welcome to today's conference call to discuss our fourth quarter and full year 2023 financial results and corporate update.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Q4 2023 <em>Agile</em> <em>Therapeutics</em> <em>Inc</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "aea8dda3-1e74-4f88-922c-88fe2f9445ad",
"title": "Q4 2023 Inhibikase Therapeutics Inc Earnings Call Transcript",
"description": "Mar 28, 2024 / 12:00PM GMTOperator Ladies and gentlemen, thank you for standing by. Greetings, and welcome to Inhibikase Therapeutics fourth-quarter and full-ye",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NAS:IKT",
"snippet": "Mar 28, 2024 / 12:00PM GMT\n\nOperator\n\n\n\nLadies and gentlemen, thank you for standing by. Greetings, and welcome to Inhibikase Therapeutics fourth-quarter and fu...",
"url": "https://www.gurufocus.com/news/2400175/q4-2023-inhibikase-therapeutics-inc-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-03-29T05:03:59.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "IKT",
"name": "Inhibikase Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 161.53055,
"sentiment_score": 0.536333,
"highlights": [
{
"highlight": "Greetings, and welcome to <em>Inhibikase</em> <em>Therapeutics</em> fourth-quarter and full-year 2023 financial results. At this time, all participants will be in listen-only mode. A question-and-answer session will follow the formal presentation. Please note that today's conference is being recorded.",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "Alex Lobo - <em>Inhibikase</em> <em>Therapeutics</em> <em>Inc</em> - Investor Relations\n\n\n\nThank you, operator. Good morning, and welcome to <em>Inhibikase</em> <em>Therapeutics</em> fourth-quarter and full-year 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "Q4 2023 <em>Inhibikase</em> <em>Therapeutics</em> <em>Inc</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "b8b9d55f-0735-44d4-8e30-3b1e043f0f8c",
"title": "3 Market-Beating Stocks to Buy in April",
"description": "Stocks Analysis by Investing.com (Jesse Cohen) covering: Nasdaq 100, S&P 500, Dow Jones Industrial Average, Chevron Corp. Read Investing.com (Jesse Cohen)'s latest article on Investing.com",
"keywords": "",
"snippet": "The S&P 500 closed out a blowout month and quarter at a new record high to notch its best start to a year since 2019.\n\nIdentifying promising opportunities becom...",
"url": "https://www.investing.com/analysis/3-marketbeating-stocks-to-buy-in-april-200647220",
"image_url": "https://i-invdn-com.investing.com/redesign/images/seo/investingcom_analysis_og.jpg",
"language": "en",
"published_at": "2024-03-29T13:07:00.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVDA",
"name": "NVIDIA Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 9.141659,
"sentiment_score": 0.7322,
"highlights": [
{
"highlight": "Driving the gains on the month and quarter has been <em>Nvidia</em> (NASDAQ: ), which is now the third most valuable company listed on the U.S. stock exchange. NVDA stock gained 14.2% in March and soared 82.5% for the quarter as the AI boom shows no signs of slowing.",
"sentiment": 0.7322,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "d7fb1e1d-7663-41ff-8d33-fb7312def622",
"title": "20VC: The Memo: The $23BN Company You Have Not Heard Of: Tradeweb, The Story of 27 Years of Compounding Growth Leading to the Market Leader with $1.4BN in Revenue and 50% EBITDA Margins",
"description": "Billy Hult is Chief Executive Officer of Tradeweb Markets. TradeWeb has compounded organic growth with a market cap of $22BN.",
"keywords": "",
"snippet": "Billy Hult is Chief Executive Officer of Tradeweb Markets (Nasdaq: TW), as Billy puts it, they are the “electronic interface that connects Citadel and Goldman...",
"url": "https://www.thetwentyminutevc.com/billy-hult/",
"image_url": "https://www.thetwentyminutevc.com/wp-content/uploads/2024/03/WhatsApp-Image-2024-03-28-at-4.38.39-PM.jpeg",
"language": "en",
"published_at": "2024-03-29T13:03:09.000000Z",
"source": "thetwentyminutevc.com",
"relevance_score": null,
"entities": [
{
"symbol": "TW",
"name": "Tradeweb Markets Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 38.302696,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Billy Hult is Chief Executive Officer of <em>Tradeweb</em> <em>Markets</em> (<em>Nasdaq</em>: <em>TW</em>), as Billy puts it, they are the “electronic interface that connects Citadel and Goldman”. They are also one of the most under the radar but incredible businesses of the last 20 years.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "77e1797a-cdd8-47f9-9308-20e586f84eb6",
"title": "Apple Will Have To ‘Rethink’ iPhone 16 Design After New Law",
"description": "Apple will have to \"rethink\" the design of its next iPhone if it wants to comply with a new right-to-repair law, a repair specialist claims.",
"keywords": "Apple, iPhone 15, NASDAQ: AAPL, iphone 15 repair, iphone se22, iphone 16, iphone 14, iphone 15 charger, when is iphone 17 coming out, what will iphone 16 look like",
"snippet": "iPhone 15 Pro Max smartphones on display inside the Apple Inc. Puerta del Sol store on the first day ... [+] of sale of the iPhone 15 smartphone in Madrid, Spai...",
"url": "https://www.forbes.com/sites/jaymcgregor/2024/03/29/apple-iphone-16-design-right-to-repair-law-oregon-sb1596/",
"image_url": "https://imageio.forbes.com/specials-images/imageserve/656c7e60cc22db89d3b49fe0/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
"language": "en",
"published_at": "2024-03-29T13:03:05.000000Z",
"source": "forbes.com",
"relevance_score": null,
"entities": [
{
"symbol": "AAPL",
"name": "Apple Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 23.909817,
"sentiment_score": 0.2295,
"highlights": [
{
"highlight": "iPhone 15 Pro Max smartphones on display inside the <em>Apple</em> <em>Inc</em>. Puerta del Sol store on the first day ... [+] of sale of the iPhone 15 smartphone in Madrid, Spain, on Friday, Sept. 22, 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Photographer: Manaure Quintero/Bloomberg © 2023 Bloomberg Finance LP\n\n<em>Apple</em> will have to “rethink” the design of its next iPhone if it wants to comply with a new right-to-repair law, a repair specialist claims.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Ricky Panesar, co-founder of iCorrect.co.uk and someone who has discovered repair roadblocks in several <em>Apple</em> devices, says that <em>Apple</em> will have to change its practices when it comes to parts pairing, after a new repair bill was signed into law by Oregon Governor Tina Kotek on March 27th.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "\"<em>Apple</em> won’t stop selling phones, but it will have to rethink parts pairing on its devices sold after 2025. <em>Apple</em> will have to change how the next iPhone is designed. There are so many parts now that have reduced features if they’re swapped between devices. It’s such good news that this is going to stop.”",
"sentiment": 0.5023,
"highlighted_in": "main_text"
},
{
"highlight": "That tool is only available to <em>Apple</em> and <em>Apple</em>-certified repair shops.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "It’s the same with the <em>Apple</em> Pencil, which won’t draw straight lines if it's being used on an iPad Pro that has had a screen replacement.\n\nBut Pansesar hopes that the new bill will change all of that. “This is huge for repair and refurbishment in the future. Parts pairing meant that everything had to go through <em>Apple</em>.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "I can’t see <em>Apple</em> undoing that, unless it is pushed by the EU or other governing bodies.”\n\nWhat happens to current iPhones with paired parts, or future devices, is indeed the big question. Will <em>Apple</em> have to change its policy and make its parts calibration tool available to everyone?",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The prospect of something similar happening again could be why <em>Apple</em> opposed the Oregon bill, despite supporting California’s slightly less aggressive Right to Repair Act last year.",
"sentiment": 0.1494,
"highlighted_in": "main_text"
},
{
"highlight": "Both <em>Apple</em> and Google (and Samsung) have improved the repairability of their devices in recent years. <em>Apple</em> created its Independent Repair Program, while Google has upped its promise of software support to seven years.",
"sentiment": 0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "But parts pairing has remained a dividing line between the two companies and in testifying in favor of this bill, Google likely knows that it will hurt <em>Apple</em>. What happens next and how <em>Apple</em> responds will be one of the more interesting technology dramas to watch in the coming year.",
"sentiment": 0.3102,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Apple</em> Will Have To ‘Rethink’ iPhone 16 Design After New Law",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NASDAQ",
"total_documents": 1236,
"sentiment_avg": 0.279177540504945
}
]
}
Other details
Country
- us
- 5,275